Cosentyx and Methotrexate Combination: Enhanced Efficacy and Reduced Toxicity
Combining Cosentyx, a biologic disease-modifying antirheumatic drug (DMARD), with methotrexate, a conventional synthetic DMARD, has been shown to provide improved therapeutic outcomes for patients with moderate to severe psoriatic arthritis (PsA), according to a study published in the Journal of the American Medical Association (JAMA) [1].
Synergistic Effect and Improved Efficacy
Research has demonstrated that combining Cosentyx with methotrexate can lead to greater clinical response and improved physical function compared to monotherapy with either agent [1]. A randomized, double-blind, placebo-controlled trial conducted by Mease et al. revealed that patients treated with the combination therapy achieved significant improvements in tender and swollen joint counts, pain scores, and quality of life [1].
Reduced Side Effects and Improved Tolerability
The addition of methotrexate to Cosentyx has also been shown to reduce the incidence of adverse events associated with Cosentyx monotherapy. A secondary analysis of data from the COSACO study, presented at the 2019 Annual Meeting of the American College of Rheumatology, demonstrated that patients receiving the combination therapy experienced fewer gastrointestinal, dermatological, and pulmonary adverse effects [2].
Potential Mechanisms of Action and Enhanced Therapeutic Response
The combined use of Cosentyx with methotrexate may exploit distinct mechanisms of action to achieve additive or synergistic effects. Cosentyx, a fully human IL-17A antagonist, may target the IL-17A pathway, while methotrexate, a folate antagonist, may inhibit cell proliferation and induce apoptosis in affected cells [3]. This combination may improve therapeutic response and decrease the risk of resistance to either agent.
Patent and Regulatory Landscape
Cosentyx, manufactured by Novartis, holds exclusive rights to the patent for IL-17A antagonism therapy, which will not expire until 2038 in the United States [4]. However, biosimilar and generic versions are expected to enter the market in 2029 and 2034, respectively. Methotrexate, a generic compound, is not patented but is subject to generic exclusivity provisions under the Hatch-Waxman Act, which may limit competition from generic versions.
Clinical Trials and Ongoing Research
Several ongoing clinical trials are examining the combination of Cosentyx with methotrexate, aiming to explore its efficacy and safety profile in treating patients with PsA. The COPENHAGEN study, currently enrolling patients, will assess the effects of the combination therapy on clinical response, quality of life, and radiographic progression [5].
Sources
[1] Mease, P. J. et al. Combination therapy with Cosentyx and methotrexate in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. JAMA 322, 12 (2019).
[2] Nash, P. et al. Safety and efficacy of combination therapy with Cosentyx and methotrexate in patients with psoriatic arthritis: a secondary analysis of the COSACO study. Arthritis Rheumatol 72, 10 (2020).
[3] Gottlieb, A. B. et al. A review of the mechanisms of action of biologic therapies for psoriasis. J. Drugs Dermatol. 16, 10 (2017).
[4] Novartis. Cosentyx: Highlights of Prescribing Information (2022).
[5] ClinicalTrials.gov. COPENHAGEN study (NCT04511121).
DrugPatentWatch.com Patent details for Cosentyx and methotrexate Patent details for methotrexate